BACKGROUND: Mitofusin 2 (MFN2) is a mitochondrial membrane protein mediating mitochondrial fusion and function. Mutated MFN2 is responsible for Charcot-Marie-Tooth type 2A2. In small kindreds, specific MFN2 mutations have been reported to associate with severity of axonal neuropathy, optic atrophy, and involvement of the central nervous system. The results of the nerve biopsy specimens suggested that the mitochondria are structurally abnormal in patients with MFN2 mutations. OBJECTIVE: To study a newly identified MFN2 mutation, Leu146Phe, and the associated phenotypes in a large kindred. PATIENTS: An American kindred of Northern European and Cherokee American Indian descent. RESULTS: Genetic analysis revealed a novel GTPase domain MFN2 mutation Leu146Phe that associated with clinical status of 15 studied persons (10 affected and 5 unaffected) and not found in 800 control persons. Clinical manifestations were markedly different. In 1 affected person, optic atrophy and brain magnetic resonance imaging abnormalities led to multiple sclerosis diagnosis and interferon β-1a treatment when neuropathy was initially unrecognized. Age of onset ranged from 1 to 45 years. In some affected family members, severe and rapid-onset motor sensory neuropathy led to early loss of ambulation, whereas other family members experienced minimal neuropathic sensory symptoms. Despite histologically significant loss of nerve fibers, the mitochondria were not distinguishable from diseased sural nerve biopsy specimens and healthy controls. CONCLUSIONS: Novel MFN2 mutation Leu146Phe causes Charcot-Marie-Tooth type 2A2. Intrafamilial clinical phenotype variability is emphasized and has important implications in genetic counseling. The clinical phenotype may mimic multiple sclerosis when optic atrophy and the characteristic brain lesions of MFN2 on magnetic resonance imaging are present and neuropathy is mild or unrecognized. The predicted molecular pathogenesis may occur without evident histological abnormalities of mitochondria in nerve.
BACKGROUND:Mitofusin 2 (MFN2) is a mitochondrial membrane protein mediating mitochondrial fusion and function. Mutated MFN2 is responsible for Charcot-Marie-Tooth type 2A2. In small kindreds, specific MFN2 mutations have been reported to associate with severity of axonal neuropathy, optic atrophy, and involvement of the central nervous system. The results of the nerve biopsy specimens suggested that the mitochondria are structurally abnormal in patients with MFN2 mutations. OBJECTIVE: To study a newly identified MFN2 mutation, Leu146Phe, and the associated phenotypes in a large kindred. PATIENTS: An American kindred of Northern European and Cherokee American Indian descent. RESULTS: Genetic analysis revealed a novel GTPase domain MFN2 mutation Leu146Phe that associated with clinical status of 15 studied persons (10 affected and 5 unaffected) and not found in 800 control persons. Clinical manifestations were markedly different. In 1 affected person, optic atrophy and brain magnetic resonance imaging abnormalities led to multiple sclerosis diagnosis and interferon β-1a treatment when neuropathy was initially unrecognized. Age of onset ranged from 1 to 45 years. In some affected family members, severe and rapid-onset motor sensory neuropathy led to early loss of ambulation, whereas other family members experienced minimal neuropathic sensory symptoms. Despite histologically significant loss of nerve fibers, the mitochondria were not distinguishable from diseased sural nerve biopsy specimens and healthy controls. CONCLUSIONS: Novel MFN2 mutation Leu146Phe causes Charcot-Marie-Tooth type 2A2. Intrafamilial clinical phenotype variability is emphasized and has important implications in genetic counseling. The clinical phenotype may mimic multiple sclerosis when optic atrophy and the characteristic brain lesions of MFN2 on magnetic resonance imaging are present and neuropathy is mild or unrecognized. The predicted molecular pathogenesis may occur without evident histological abnormalities of mitochondria in nerve.
Authors: F Boaretto; A Vettori; A Casarin; G Vazza; M Muglia; M G Rossetto; T Cavallaro; N Rizzuto; V Carelli; L Salviati; M L Mostacciuolo; A Martinuzzi Journal: Neurology Date: 2010-06-08 Impact factor: 9.910
Authors: K W Chung; S B Kim; K D Park; K G Choi; J H Lee; H W Eun; J S Suh; J H Hwang; W K Kim; B C Seo; S H Kim; I H Son; S M Kim; I N Sunwoo; B O Choi Journal: Brain Date: 2006-07-10 Impact factor: 13.501
Authors: Jean-Michel Vallat; Robert A Ouvrier; John D Pollard; Corinne Magdelaine; Danqing Zhu; Garth A Nicholson; Simon Grew; Monique M Ryan; Benoît Funalot Journal: J Neuropathol Exp Neurol Date: 2008-11 Impact factor: 3.685
Authors: G A Nicholson; C Magdelaine; D Zhu; S Grew; M M Ryan; F Sturtz; J-M Vallat; R A Ouvrier Journal: Neurology Date: 2008-05-06 Impact factor: 9.910
Authors: R Del Bo; M Moggio; M Rango; S Bonato; M G D'Angelo; S Ghezzi; G Airoldi; M T Bassi; M Guglieri; L Napoli; C Lamperti; S Corti; A Federico; N Bresolin; G P Comi Journal: Neurology Date: 2008-10-22 Impact factor: 9.910
Authors: Yueqin Zhou; Sharon Carmona; A K M G Muhammad; Shaughn Bell; Jesse Landeros; Michael Vazquez; Ritchie Ho; Antonietta Franco; Bin Lu; Gerald W Dorn; Shaomei Wang; Cathleen M Lutz; Robert H Baloh Journal: J Clin Invest Date: 2019-03-18 Impact factor: 14.808
Authors: Lois Dankwa; Jessica Richardson; William W Motley; Mena Scavina; Steve Courel; Tanya Bardakjian; Stephan Züchner; Steven S Scherer Journal: Neuromuscul Disord Date: 2018-12-21 Impact factor: 4.296
Authors: Menelaos Pipis; Shawna M E Feely; James M Polke; Mariola Skorupinska; Laura Perez; Rosemary R Shy; Matilde Laura; Jasper M Morrow; Isabella Moroni; Chiara Pisciotta; Franco Taroni; Dragan Vujovic; Thomas E Lloyd; Gyula Acsadi; Sabrina W Yum; Richard A Lewis; Richard S Finkel; David N Herrmann; John W Day; Jun Li; Mario Saporta; Reza Sadjadi; David Walk; Joshua Burns; Francesco Muntoni; Sindhu Ramchandren; Rita Horvath; Nicholas E Johnson; Stephan Züchner; Davide Pareyson; Steven S Scherer; Alexander M Rossor; Michael E Shy; Mary M Reilly Journal: Brain Date: 2020-12-01 Impact factor: 13.501